Update: See our article discussing notable points from the Draft Guidelines.
Following its Phase 2 Consultations, on December 19, 2024, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview. The deadline for providing submissions on the Draft Guidelines is March 19, 2025. The PMPRB continues to plan to release its final Guidelines in 2025.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency announces consultation on streamlined review process and new reconsideration/resubmission procedures
On January 29, 2026, Canada’s Drug Agency (CDA) published Improvements to the Drug Reimbursement Review Process, which includes a section for consultation on proposed changes to the reimbursement re...Read More -
PMPRB consults on proposed Practice Directions for PMPRB hearings
The Patented Medicine Prices Review Board (PMPRB) holds public hearings in two types of matters: to determine whether the price of a medicine is excessive; and to determine whether a rights holder ha...Read More -
Canada announces new Pharmaceutical and Life Sciences Sector Task Force
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and ...Read More
